Drug intelligence / Profile preview

WTYX10003

Development stage: Preclinical
Lead developer: Xiamen Innovax Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

WTYX10003 is an investigational vaccine being developed by Xiamen Innovax Biotech (Sino-Innovax Biotech) for the prevention of hand, foot, and mouth disease (HFMD), herpangina, and other related enterovirus diseases. The vaccine is designed to target enteroviruses, which are common pathogens responsible for these childhood infections. As of 2026, WTYX10003 is in the Clinical Trial Application (CTA) preparation phase, moving towards clinical evaluation.

Targets

Enterovirus capsid protein

Beyond the preview

Go deeper on WTYX10003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTYX10003.

Explore the full profile